Cargando…

Inhaled epoprostenol therapy for pulmonary hypertension: Improves oxygenation index more consistently in neonates than in older children

The purpose of this study was to determine the efficacy of inhaled epoprostenol for treatment of acute pulmonary hypertension (PH) in pediatric patients and to formulate a plan for a prospective, randomized study of pulmonary vasodilator therapy in this population. Inhaled epoprostenol is an effecti...

Descripción completa

Detalles Bibliográficos
Autores principales: Brown, Anna T., Gillespie, Jennifer V., Miquel-Verges, Franscesca, Holmes, Kathryn, Ravekes, William, Spevak, Philip, Brady, Ken, Easley, R. Blaine, Golden, W. Christopher, McNamara, LeAnn, Veltri, Michael A., Lehmann, Christoph U., McMillan, Kristen Nelson, Schwartz, Jamie M., Romer, Lewis H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3342750/
https://www.ncbi.nlm.nih.gov/pubmed/22558521
http://dx.doi.org/10.4103/2045-8932.94835
_version_ 1782231728108077056
author Brown, Anna T.
Gillespie, Jennifer V.
Miquel-Verges, Franscesca
Holmes, Kathryn
Ravekes, William
Spevak, Philip
Brady, Ken
Easley, R. Blaine
Golden, W. Christopher
McNamara, LeAnn
Veltri, Michael A.
Lehmann, Christoph U.
McMillan, Kristen Nelson
Schwartz, Jamie M.
Romer, Lewis H.
author_facet Brown, Anna T.
Gillespie, Jennifer V.
Miquel-Verges, Franscesca
Holmes, Kathryn
Ravekes, William
Spevak, Philip
Brady, Ken
Easley, R. Blaine
Golden, W. Christopher
McNamara, LeAnn
Veltri, Michael A.
Lehmann, Christoph U.
McMillan, Kristen Nelson
Schwartz, Jamie M.
Romer, Lewis H.
author_sort Brown, Anna T.
collection PubMed
description The purpose of this study was to determine the efficacy of inhaled epoprostenol for treatment of acute pulmonary hypertension (PH) in pediatric patients and to formulate a plan for a prospective, randomized study of pulmonary vasodilator therapy in this population. Inhaled epoprostenol is an effective treatment for pediatric PH. A retrospective chart review was conducted of all pediatric patients who received inhaled epoprostenol at a tertiary care hospital between October 2005 and August 2007. The study population was restricted to all patients under 18 years of age who received inhaled epoprostenol for greater than 1 hour and had available data for oxygenation index (OI) calculation. Arterial blood gas values and ventilator settings were collected immediately prior to epoprostenol initiation, and during epoprostenol therapy (as close to 12 hours after initiation as possible). Echocardiograms were reviewed during two time frames: Within 48 hours prior to therapy initiation and within 96 hours after initiation. Of the 20 patients in the study population, 13 were neonates, and the mean OI for these patients improved during epoprostenol administration (mean OI before and during therapy was 25.6±16.3 and 14.5±13.6, respectively, P=0.02). Mean OI for the seven patients greater than 30 days of age was not significantly different during treatment (mean OI before and during therapy was 29.6±15.0 and 25.6±17.8, P=0.56). Improvement in echocardiographic findings (evidence of decreased right-sided pressures or improved right ventricular function) was demonstrated in 20% of all patients. Inhaled epoprostenol is an effective therapy for the treatment of selected pediatric patients with acute PH. Neonates may benefit more consistently from this therapy than older infants and children. A randomized controlled trial is needed to discern the optimal role for inhaled prostanoids in the treatment of acute PH in childhood.
format Online
Article
Text
id pubmed-3342750
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Medknow Publications & Media Pvt Ltd
record_format MEDLINE/PubMed
spelling pubmed-33427502012-05-03 Inhaled epoprostenol therapy for pulmonary hypertension: Improves oxygenation index more consistently in neonates than in older children Brown, Anna T. Gillespie, Jennifer V. Miquel-Verges, Franscesca Holmes, Kathryn Ravekes, William Spevak, Philip Brady, Ken Easley, R. Blaine Golden, W. Christopher McNamara, LeAnn Veltri, Michael A. Lehmann, Christoph U. McMillan, Kristen Nelson Schwartz, Jamie M. Romer, Lewis H. Pulm Circ Research Article The purpose of this study was to determine the efficacy of inhaled epoprostenol for treatment of acute pulmonary hypertension (PH) in pediatric patients and to formulate a plan for a prospective, randomized study of pulmonary vasodilator therapy in this population. Inhaled epoprostenol is an effective treatment for pediatric PH. A retrospective chart review was conducted of all pediatric patients who received inhaled epoprostenol at a tertiary care hospital between October 2005 and August 2007. The study population was restricted to all patients under 18 years of age who received inhaled epoprostenol for greater than 1 hour and had available data for oxygenation index (OI) calculation. Arterial blood gas values and ventilator settings were collected immediately prior to epoprostenol initiation, and during epoprostenol therapy (as close to 12 hours after initiation as possible). Echocardiograms were reviewed during two time frames: Within 48 hours prior to therapy initiation and within 96 hours after initiation. Of the 20 patients in the study population, 13 were neonates, and the mean OI for these patients improved during epoprostenol administration (mean OI before and during therapy was 25.6±16.3 and 14.5±13.6, respectively, P=0.02). Mean OI for the seven patients greater than 30 days of age was not significantly different during treatment (mean OI before and during therapy was 29.6±15.0 and 25.6±17.8, P=0.56). Improvement in echocardiographic findings (evidence of decreased right-sided pressures or improved right ventricular function) was demonstrated in 20% of all patients. Inhaled epoprostenol is an effective therapy for the treatment of selected pediatric patients with acute PH. Neonates may benefit more consistently from this therapy than older infants and children. A randomized controlled trial is needed to discern the optimal role for inhaled prostanoids in the treatment of acute PH in childhood. Medknow Publications & Media Pvt Ltd 2012 /pmc/articles/PMC3342750/ /pubmed/22558521 http://dx.doi.org/10.4103/2045-8932.94835 Text en Copyright: © Pulmonary Circulation http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Brown, Anna T.
Gillespie, Jennifer V.
Miquel-Verges, Franscesca
Holmes, Kathryn
Ravekes, William
Spevak, Philip
Brady, Ken
Easley, R. Blaine
Golden, W. Christopher
McNamara, LeAnn
Veltri, Michael A.
Lehmann, Christoph U.
McMillan, Kristen Nelson
Schwartz, Jamie M.
Romer, Lewis H.
Inhaled epoprostenol therapy for pulmonary hypertension: Improves oxygenation index more consistently in neonates than in older children
title Inhaled epoprostenol therapy for pulmonary hypertension: Improves oxygenation index more consistently in neonates than in older children
title_full Inhaled epoprostenol therapy for pulmonary hypertension: Improves oxygenation index more consistently in neonates than in older children
title_fullStr Inhaled epoprostenol therapy for pulmonary hypertension: Improves oxygenation index more consistently in neonates than in older children
title_full_unstemmed Inhaled epoprostenol therapy for pulmonary hypertension: Improves oxygenation index more consistently in neonates than in older children
title_short Inhaled epoprostenol therapy for pulmonary hypertension: Improves oxygenation index more consistently in neonates than in older children
title_sort inhaled epoprostenol therapy for pulmonary hypertension: improves oxygenation index more consistently in neonates than in older children
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3342750/
https://www.ncbi.nlm.nih.gov/pubmed/22558521
http://dx.doi.org/10.4103/2045-8932.94835
work_keys_str_mv AT brownannat inhaledepoprostenoltherapyforpulmonaryhypertensionimprovesoxygenationindexmoreconsistentlyinneonatesthaninolderchildren
AT gillespiejenniferv inhaledepoprostenoltherapyforpulmonaryhypertensionimprovesoxygenationindexmoreconsistentlyinneonatesthaninolderchildren
AT miquelvergesfranscesca inhaledepoprostenoltherapyforpulmonaryhypertensionimprovesoxygenationindexmoreconsistentlyinneonatesthaninolderchildren
AT holmeskathryn inhaledepoprostenoltherapyforpulmonaryhypertensionimprovesoxygenationindexmoreconsistentlyinneonatesthaninolderchildren
AT ravekeswilliam inhaledepoprostenoltherapyforpulmonaryhypertensionimprovesoxygenationindexmoreconsistentlyinneonatesthaninolderchildren
AT spevakphilip inhaledepoprostenoltherapyforpulmonaryhypertensionimprovesoxygenationindexmoreconsistentlyinneonatesthaninolderchildren
AT bradyken inhaledepoprostenoltherapyforpulmonaryhypertensionimprovesoxygenationindexmoreconsistentlyinneonatesthaninolderchildren
AT easleyrblaine inhaledepoprostenoltherapyforpulmonaryhypertensionimprovesoxygenationindexmoreconsistentlyinneonatesthaninolderchildren
AT goldenwchristopher inhaledepoprostenoltherapyforpulmonaryhypertensionimprovesoxygenationindexmoreconsistentlyinneonatesthaninolderchildren
AT mcnamaraleann inhaledepoprostenoltherapyforpulmonaryhypertensionimprovesoxygenationindexmoreconsistentlyinneonatesthaninolderchildren
AT veltrimichaela inhaledepoprostenoltherapyforpulmonaryhypertensionimprovesoxygenationindexmoreconsistentlyinneonatesthaninolderchildren
AT lehmannchristophu inhaledepoprostenoltherapyforpulmonaryhypertensionimprovesoxygenationindexmoreconsistentlyinneonatesthaninolderchildren
AT mcmillankristennelson inhaledepoprostenoltherapyforpulmonaryhypertensionimprovesoxygenationindexmoreconsistentlyinneonatesthaninolderchildren
AT schwartzjamiem inhaledepoprostenoltherapyforpulmonaryhypertensionimprovesoxygenationindexmoreconsistentlyinneonatesthaninolderchildren
AT romerlewish inhaledepoprostenoltherapyforpulmonaryhypertensionimprovesoxygenationindexmoreconsistentlyinneonatesthaninolderchildren